The sexually transmitted disease gonorrhea is now among the ''superbugs" resistant to common antibiotics, leading U.S. health officials to recommend wider use of a different class of drugs to avert a public-health crisis.
The resistant form accounts for more than one in every four gonorrhea cases among heterosexual men in Philadelphia and nearly that many in San Francisco, according to a survey that led to Thursday's recommendation by the Centers for Disease Control and Prevention.
Gonorrhea, which is believed to infect more than 700,000 people in the United States each year, can leave both men and women infertile and puts people at higher risk of getting the AIDS virus.
Since the early 1990s a class of drugs known as fluoroquinolones has provided a relatively easy cure. These antibiotics, taken as tablets, include the drug Cipro.
But a growing number of gonorrhea cases is resistant to those drugs, and officials at the CDC for the first time are urging doctors to stop using fluoroquinolones and switch to cephalosporins, a different class of antibiotics, to treat everyone.
Those drugs—which include the generic ceftriaxone, or brand name Rocephin, made by Swiss drugmaker Roche Holding AG—must be given as a shot and aren't as readily stocked as Cipro on most doctor's shelves.
''Gonorrhea has now joined the list of other superbugs for which treatment options have become dangerously few,'' said Henry Masur, president of the Infectious Diseases Society of America. ''To make a bad problem even worse, we're also seeing a decline in the development of new antibiotics to treat these infections.''
The CDC made the new recommendation after discovering that nearly 7% of gonorrhea cases among heterosexual men in a survey of 26 U.S. cities last year were drug-resistant. In 2001 only about 0.6% of gonorrhea cases among heterosexual men were drug-resistant.
''That leaves us with a single class of highly effective antibiotics,'' said John Douglas Jr., director of the CDC's division of STD prevention. Other experts called the situation perilous.
''We are running out of options to treat this disease,'' added Douglas, who said there are ''no new drugs for gonorrhea in the drug development pipeline.''
Previously, CDC recommended against fluoroquinolones to treat drug-resistant gonorrhea among men who have sex with men and in certain states, including California and Hawaii, where most of these cases were turning up.
Described by Douglas as a ''very wily'' disease, gonorrhea has worked its way through decades of other treatment regimens, from sulfa drugs used in the 1930s and 1940s, to penicillin, which was used from the 1940s until the mid 1980s.
Gonorrhea, spread through sexual contact, is the second most commonly reported infectious disease in the United States, trailing only chlamydia, which the CDC says affects more than 2.1 million people yearly in the U.S.
The highest rates of infection are among sexually active teens, young adults, and African-Americans. Because many people don't have obvious symptoms, they can unknowingly spread it to others. And having it makes people more susceptible to HIV. Gonorrhea's spread is preventable through consistent and proper use of condoms, experts said.
In women the infection can cause pelvic inflammatory disease. In men it can cause epididymitis, a painful condition of the testicles that can lead to infertility if untreated, the CDC said.
In the survey of gonorrhea cases among heterosexual men in 26 cities last year, Philadelphia had the highest percentage of drug-resistant cases with almost 27%, a dramatic increase from only 1.2% in 2004.
San Francisco's drug-resistant cases more than doubled between 2004 and 2006, from 10.3% to 22.5%. During the same period Miami's cases spiked from 2.1% to 15.3% and Atlanta's climbed from 1% to 5.7%. (AP)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.
Home | Contact | Current Issue | LGBT Community Partners | Staff
Career Opportunities | Help
Subscribe: Print Edition Digital Edition | Subscriber Services: Print Edition Digital Edition
Visit our Websites
Out.com | OutTraveler.com | HIVPlusMag.com | Alyson.com | HereTV.com | GayWired.com | SheWired.com
Privacy Policy | User Agreement | Community Guidelines | Legal Notice
Advocate.com © 2009 Regent Entertainment Media Inc. All Rights Reserved.
